Clinical Trials Logo

Type 2 Diabetes Mellitus clinical trials

View clinical trials related to Type 2 Diabetes Mellitus.

Filter by:

NCT ID: NCT03864432 Completed - Clinical trials for Type 2 Diabetes Mellitus

An Ascending Dose, Single/Multiple Dosing, Food Effect Clinical Trial to Evaluate Pharmacokinetics, Safety and Tolerability in Healthy Subjects After Oral Administration of Gemigliptin (Phase I)

Start date: July 2, 2019
Phase: Phase 1
Study type: Interventional

To determine the pharmacokinetic properties, safety and tolerability of single/multiple oral administration of Gemigliptin and Food effect in healthy Chinese subjects.

NCT ID: NCT03862963 Completed - Clinical trials for Type 2 Diabetes Mellitus

Lifestyle Intervention to Treat Diabetes in the Marshall Islands

Start date: June 1, 2006
Phase: N/A
Study type: Interventional

The Republic of the Marshall Islands has the highest prevalence of type 2 diabetes (T2D) in the world. This clinical trial tested whether a community-based, intensive, plant-rich lifestyle intervention with exercise is more effective for treating and managing T2D in the Republic of the Marshall Islands than the standard of diabetes care. The intensive lifestyle intervention consisted of a plant-rich diet and moderate exercise. It centered around a 12-week program of counseling and instruction on healthy eating, exercise, and stress management, as well as hands-on cooking classes and prepared meals. Cardiometabolic outcomes were assessed throughout the intervention and at 24 weeks. The present study is the first randomized clinical trial ever conducted in the Republic of the Marshall Islands and the first lifestyle intervention trial conducted in Micronesia.

NCT ID: NCT03862716 Completed - Clinical trials for Type 2 Diabetes Mellitus

Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IDegLira

REMITiDegLira
Start date: April 23, 2019
Phase: Phase 3
Study type: Interventional

The purpose of the study is to determine whether in patients with early type 2 diabetes, a short-term intensive metabolic intervention comprising IDegLira, metformin, and lifestyle approaches will be superior to standard diabetes therapy in achieving sustained diabetes remission.

NCT ID: NCT03861039 Completed - Clinical trials for Type 2 Diabetes Mellitus

A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes

Start date: March 30, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the long-term safety of the study drug tirzepatide in combination with oral antihyperglycemic medications in participants with type 2 diabetes.

NCT ID: NCT03859934 Completed - Clinical trials for Type 2 Diabetes Mellitus

Metabolic Effects of Melatonin Treatment

Start date: September 26, 2019
Phase: Phase 1
Study type: Interventional

Modern living is associated with an epidemic of type 2 diabetes mellitus (T2DM). Sleep disturbances such as insomnia or frequent awakenings are strong risk factors for T2DM with several studies indicating a central role of melatonin. Additionally, a certain single nucleotide polymorphism in the melatonin receptor gene, MTNR1B rs10830963, with an allele frequency of 30 %, is associated with increased fasting plasma glucose and T2DM. Due to treatment of, among other things, insomnia, the use of melatonin is increasing rapidly in Denmark with a 100-fold increase from 2007-2012 in children and adolescents. No previous studies have thoroughly assessed changes in glucose and fatty acid metabolism after 3 months of melatonin treatment in patients with T2DM.

NCT ID: NCT03840850 Completed - Clinical trials for Type 2 Diabetes Mellitus

Type 2 Diabetes: Risk Perceptions and Self-management Behaviour

Start date: September 15, 2017
Phase: N/A
Study type: Interventional

This pilot randomised controlled trial (RCT) aims to assess the feasibility of using a new type of risk communication intervention for people with Type 2 diabetes mellitus (T2DM) in primary care and to evaluate its potential impact on risk perceptions and self-management behaviour. The study comprises 40 participants with T2DM randomly allocated to usual care supported by the risk communication intervention or usual care only.

NCT ID: NCT03837405 Completed - Clinical trials for Type 2 Diabetes Mellitus

(R33 Phase) Delish Study: Diabetes Education to Lower Insulin, Sugars, and Hunger

Delish R33
Start date: December 12, 2018
Phase: N/A
Study type: Interventional

The investigators plan an R33 phase trial in which 120 persons with type 2 diabetes (T2DM) will be randomized (using a 1:1 ratio) to education alone (Ed) on following a carbohydrate restricted diet for T2DM, or this same education content with added mindful eating/Mindfulness-Based Intervention components (Ed+MBI).

NCT ID: NCT03829891 Completed - Clinical trials for Type 2 Diabetes Mellitus

Study for Beinaglutide Versus Glargine Therapy in Glycemic Variability of Type 2 Diabetes Mellitus

Start date: August 7, 2018
Phase: N/A
Study type: Interventional

The investigators aimed to assess the efficacy and safety of Beinaglutide versus glargine , in individuals with type 2 diabetes who did not achieve adequate glycaemic control with oral antidiabetic drug.

NCT ID: NCT03818581 Completed - Clinical trials for Type 2 Diabetes Mellitus

Suvorexant on Sleep Disturbance in Patients With Chronic Insomnia and Suboptimally Controlled Type 2 Diabetes

Start date: March 15, 2019
Phase: Phase 4
Study type: Interventional

The investigators aim to determine the effect of suvorexant on subjective total sleep time (TST) in suboptimally controlled Type 2 diabetics with chronic insomnia in a randomized placebo-controlled trial for 3 months.

NCT ID: NCT03802487 Completed - Clinical trials for Type 2 Diabetes Mellitus

Study To Determine Bioavailability of Sotagliflozin in Healthy Male and Female Subjects

Start date: January 14, 2019
Phase: Phase 1
Study type: Interventional

Primary Objective: To assess the absolute bioavailability of sotagliflozin via administration of an intravenous (IV) microdose of a 14C-sotagliflozin tracer on top of a single oral dose of unlabeled sotagliflozin without charcoal administration Secondary Objectives: - To assess the PK of sotagliflozin and its main metabolite sotagliflozin-3-O-glucuronide (M19) after a single oral dose of sotagliflozin and an IV microdose of a 14C-sotagliflozin tracer without charcoal administration - To assess the safety and tolerability of single doses of sotagliflozin when administered with and without charcoal